SCHEMBL14821484

SCHEMBL14821484

O=C(O)CNC(=O)COc1ccc(C(=O)c2ccc(N=C=S)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 8/20 0.49
▸ ALDH1A1 P00352 7/20 0.49
▸ MAPT P10636 1/20 0.49
▸ SMN1; SMN2 Q16637 7/20 0.47
▸ HTT P42858 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ NPC1 O15118 1/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ITGB3 P05106 1/20 0.40
▸ ITGA2B P08514 1/20 0.40
▸ GALR3 O60755 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14821485 0.90 LMNA (0.49) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821004 0.89 LMNA (0.46) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821471 0.88 HSD17B10 (0.48) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL14821470 0.88 LMNA (0.46) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821467 0.88 PPARA (0.44) LMNAALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL14821476 0.87 PPARA (0.46) LMNAALDH1A1SMN1; SMN2HTTMEN1
SCHEMBL15948335 0.85 SMN1; SMN2 (0.46) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821486 0.81 ATM (0.41) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821141 0.81 SMN1; SMN2 (0.46) LMNAALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14821491 0.80 MMP2 (0.40) LMNAALDH1A1MAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2758367-B1 NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT DoubleHill GmbH (DE) 2015-11-18 — — EP disclosed
US-8987316-B2 Isocyanate and isothiocyanate compounds for cancer treatment DoubleHill GmbH (DE) 2015-03-24 — — US disclosed
US-20140228419-A1 Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment DoubleHill GmbH (DE) 2014-08-14 — — US disclosed
WO-2013041204-A1 NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT 2LUTION GmbH (DE) 2013-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228419-A1 Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment IDH3A, IDH3B, IDH2 LMNA 4743/4885ALDH1A1 431/4885MAPT 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback